The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause
mortality in diabetes I read with interest the recently published study in I Diabetes, Obesity …

Aim To assess the association between allopurinol and mortality and cardiovascular
outcomes in an allopurinol‐treated diabetes cohort. Materials and Methods We conducted a …

Background Cardiovascular disease (CVD) remains the main cause of death in patients with
type 2 diabetes (T2D). Although hyperuricemia has been associated with multiple CV …

Diabetes is a leading cause of cardiovascular and kidney disease, and novel therapies to
reduce these adverse diabetes outcomes are urgently required. Allopurinol, a uric acid …

Allopurinol lowers blood pressure in adolescents and has other vasoprotective effects.
Whether similar benefits occur in older individuals remains unclear. We hypothesized that …

Background Hyperuricemia and gout have been associated with increased cardiovascular
risk. Allopurinol is an effective urate-lowering drug. Whether lowering of urate by allopurinol …

Background Allopurinol, a xanthine oxidase inhibitor, was shown to be useful in improving
endothelial dysfunction in diabetic patients independently from their coronary status …

Background Few studies, if any, have examined cardiovascular outcomes in patients with
diabetes and gout. Both diabetes and gout are risk factors for cardiovascular disease. The …

Objectives To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of
allopurinol. Methods We carried out a population-based case–control study over the period …

Background Gout gives rise to increased risk of cardiovascular events. Gout attacks can be
effectively prevented with urate lowering drugs, and allopurinol potentially reduces …